PuSH - Publication Server of Helmholtz Zentrum München

Keppler-Hafkemeyer, A.* ; Greil, C.* ; Wratil, P.R.* ; Shoumariyeh, K.* ; Stern, M.* ; Hafkemeyer, A.* ; Ashok, D.* ; Hollaus, A.* ; Lupoli, G.* ; Priller, A.* ; Bischof, M.L.* ; Ihorst, G.* ; Engelhardt, M.* ; Marks, R.* ; Finke, J.* ; Bertrand, H.* ; Dächert, C.* ; Muenchhoff, M.* ; Badell, I.* ; Emmerich, F.* ; Halder, H.* ; Spaeth, P.M.* ; Knolle, P.A.* ; Protzer, U. ; von Bergwelt-Baildon, M.* ; Duyster, J.* ; Hartmann, T.N.* ; Moosmann, A. ; Keppler, O.T.*

Potent high-avidity neutralizing antibodies and T cell responses after COVID-19 vaccination in individuals with B cell lymphoma and multiple myeloma.

Nat. Cancer 4, 81–95 (2023)
Publ. Version/Full Text Research data DOI PMC
Open Access Gold (Paid Option)
Creative Commons Lizenzvertrag
Individuals with hematologic malignancies are at increased risk for severe coronavirus disease 2019 (COVID-19), yet profound analyses of COVID-19 vaccine-induced immunity are scarce. Here we present an observational study with expanded methodological analysis of a longitudinal, primarily BNT162b2 mRNA-vaccinated cohort of 60 infection-naive individuals with B cell lymphomas and multiple myeloma. We show that many of these individuals, despite markedly lower anti-spike IgG titers, rapidly develop potent infection neutralization capacities against several severe acute respiratory syndrome coronavirus 2 variants of concern (VoCs). The observed increased neutralization capacity per anti-spike antibody unit was paralleled by an early step increase in antibody avidity between the second and third vaccination. All individuals with hematologic malignancies, including those depleted of B cells and individuals with multiple myeloma, exhibited a robust T cell response to peptides derived from the spike protein of VoCs Delta and Omicron (BA.1). Consistently, breakthrough infections were mainly of mild to moderate severity. We conclude that COVID-19 vaccination can induce broad antiviral immunity including ultrapotent neutralizing antibodies with high avidity in different hematologic malignancies.
Altmetric
Additional Metrics?
[➜Log in]
Edit extra informations Login
Publication type Article: Journal article
Document type Scientific Article
Corresponding Author
ISSN (print) / ISBN 2662-1347
e-ISSN 2662-1347
Journal Nature Cancer
Quellenangaben Volume: 4, Issue: , Pages: 81–95 Article Number: , Supplement: ,
Publisher Springer
Non-patent literature Publications
Reviewing status Peer reviewed
Institute(s) Research Unit Gene Vector (AGV)
Institute of Virology (VIRO)